Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. (trading symbol: CBIO) on April 4, 2023. The report addresses a critical corporate governance event regarding the company's continued listing status on The Nasdaq Capital Market. The company is currently engaged in a proposed business combination with Continent Pharmaceuticals Inc. (CPI) and other contributors, finalized via an agreement dated December 26, 2022, and amended on March 29, 2023.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it explicitly states the financial metric triggering the regulatory notice:
- Stockholders' Equity: The company failed to meet the Nasdaq Listing Rule 5550(b)(1) minimum requirement of $2,500,000.
- Alternative Compliance: The company also failed to meet alternative listing standards regarding the market value of listed securities or net income from continuing operations.
Material Changes and Events
On April 4, 2023, Catalyst received a written notice from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement. This event represents a material change in the company's regulatory standing. Under Nasdaq rules, the company has 45 calendar days to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 calendar days to evidence compliance.
Outlook, Risks, and Management Commentary
Management plans to submit a compliance plan within the specified timeframe but notes there is no assurance of success. The filing highlights significant risks associated with this event:
- Transaction Termination: Maintaining the Nasdaq listing is a closing condition for the proposed business combination with CPI. Delisting could result in the termination or delay of the transaction, potentially triggering termination fees and loss of benefits.
- Capital Access: Delisting could materially adversely affect access to capital markets, limit market liquidity, and reduce the stock price, hindering the company's ability to raise capital on acceptable terms.
- Forward-Looking Statements: The company cautions that actual results regarding compliance and transaction completion may differ materially from current expectations due to risks and uncertainties.
Investor Verification Checklist
- Verify the specific details of the compliance plan Catalyst intends to submit to Nasdaq within the 45-day window.
- Monitor the status of the Business Combination Agreement with Continent Pharmaceuticals Inc. (CPI) to assess the risk of termination due to delisting.
- Review the upcoming proxy statement and Form S-3 registration statement for detailed financial data and transaction terms.
- Check subsequent filings for any updates on the Nasdaq hearing or extension status.